This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sewell, D. Articles by Pfaller, M. Search for Related Content PubMed PubMed Citation Articles by Sewell, D. Articles by Pfaller, M.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, 07 1995, 1591-1595, Vol 39, No. 7
Copyright © 1995 by the American Society for Microbiology. All rights reserved.

Comparative antimicrobial activities of the penem WY-49605 (SUN5555) against recent clinical isolates from five U.S. medical centers

D Sewell, A Barry, S Allen, P Fuchs, J McLaughlin and M Pfaller
Veterans Affairs Medical Center, Portland, Oregon 97201, USA.

The in vitro activity of WY-49605 (SUN5555) (WY) was compared with those of cefaclor, cefixime, and amoxicillin-clavulanic acid against 2,958 consecutive clinical isolates from five medical centers and 402 respiratory pathogens from 18 other facilities. Most members of the family Enterobacteriaceae were inhibited by WY (MIC at which 50% of the isolates are inhibited [MIC50], < or = 2.0 micrograms/ml). MIC90s of > or = 8.0 micrograms/ml were observed for Enterobacter cloacae, Serratia spp., and Proteus mirabilis. WY was the most active drug against methicillin-susceptible Staphylococcus aureus (MIC90, 0.12 microgram/ml) and other coagulase-negative staphylococci (MIC90, 4.0 micrograms/ml). The four drugs were not active against nonenteric gram- negative bacilli, methicillin-resistant Staphylococcus aureus, and Staphylococcus haemolyticus. At 2.0 micrograms/ml, WY inhibited 82% of Enterococcus faecalis strains and was equal to or superior to the other drugs against streptococci, Haemophilus influenzae, and Moraxella catarrhalis.

This article has been cited by other articles:

• Gettig, J. P, Crank, C. W, Philbrick, A. H (2008). Faropenem Medoxomil. The Annals of Pharmacotherapy 42: 80-90 [Abstract] [Full Text]  
• Critchley, I. A., Karlowsky, J. A., Draghi, D. C., Jones, M. E., Thornsberry, C., Murfitt, K., Sahm, D. F. (2002). Activities of Faropenem, an Oral {beta}-Lactam, against Recent U.S. Isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Antimicrob. Agents Chemother. 46: 550-555 [Abstract] [Full Text]